| Literature DB >> 24250406 |
V Kanagarajan1, J Thanusu, M Gopalakrishnan.
Abstract
In a search for new leads towards potent antimicrobial agents, an array of novel (2E)-ethyl-2-(2-(2,4-dinitrophenyl)hydrazono)-4-(naphthalen-2-yl)-6-arylcyclohex-3-ene carboxylates 17-24 were synthesized and characterized through their melting point, elemental analysis, MS, FT-IR, one-dimensional NMR ((1)H, D2O exchanged (1)H and (13)C), two dimensional HOMOCOR and HSQC spectroscopic data. In-vitro microbiological evaluations were carried out for all the newly synthesized compounds 17-24 against clinically isolated bacterial strains namely Salmonella typhii, Klebsiellapneumoniae, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, β-Hemolytic streptococcus and Micrococcus luteusand also fungal strains namely Aspergillusflavus, Aspergillusniger, Mucor, Rhizopus and Microsporumgypseumand finally, the results of their structure activity relationship were discussed. The obtained results can be used as the key step for the building of novel chemical compounds with interesting antimicrobial profiles comparable to that of the standard drugs.Entities:
Keywords: (2E)-ethyl-2-(2-(2; 2; 4-Dinitrophenyl hydrazine; 4-dinitrophenyl)2hydrazono)-4-(naphthalen-2-yl) -6-arylcyclohex-3-enecarboxylates; Antibacterial activity; Antifungal activity; Ethyl 4-(naphthalen-2-yl)-2-oxo-6-arylcyclohex-3-enecarboxylates
Year: 2011 PMID: 24250406 PMCID: PMC3813054
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
Figure 1Structurally diverse clinically potent hydrazones that possess varied biological activities
Figure 2Synthesis of ethyl 4-(naphthalen-2-yl)-2-oxo-6-phenylcyclohex-3-enecarboxylates and (2E)-ethyl 2- (2-(2,4-dinitrophenyl)hydrazono)-4-(naphthalen-2yl)-6-arylcyclohex-3-enecarboxylates
Physical and analytical data of ethyl 4-(naphthalene-2-yl)-2-oxo-6-aryl cyclohex-3-enecarboxylates 9-16 and (2E)-ethyl-2-(2-(2,4-dinitrophenyl)hydrazono)-4-(naphthalen-2-yl)-6-arylcyclohex-3-enecarboxylates (compounds 9-24).
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||
|
| H | H | 2 | 80 | 146 | 81.01 (81.06) | 5.92 (5.99) | - | 371 [C25H22O3] |
|
| CH3 | H | 3 | 78 | 110 | 81.17 (81.22) | 6.25 (6.29) | - | 385 [C26H24O3] |
|
| F | H | 1 | 82 | 126 | 77.24 (77.30) | 5.40 (5.45) | - | 389 [C25H21FO3] |
|
| OCH3 | H | 3 | 80 | 122 | 77.91 (77.98) | 6.00 (6.04) | - | 401 [C26H24O4] |
|
| Cl | H | 1 | 75 | 114 | 74.12 (74.16) | 5.20 (5.23) | - | 405 [C25H21ClO3] |
|
| Br | H | 1 | 78 | 126 | 66.76 (66.82) | 4.67 (4.71) | - | 449 [C25H21BrO3] |
|
| NO2 | H | 2 | 65 | 132 | 72.22 (72.28) | 5.07 (5.10) | 3.33 (3.37) | 416 [C25H21NO5] |
|
| H | Cl | 2 | 78 | 98 | 74.10 (74.16) | 5.15 (5.23) | - | 405 [C25H21ClO3] |
|
| H | H | 2 | 82 | 125 | 67.57 (67.63) | 4.72 (4.76) | 10.12 (10.18) | 551 [C31H26N4O6] |
|
| CH3 | H | 2 | 85 | 132 | 68.03 (68.07) | 4.94 (5.00) | 9.86 (9.92) | 565 [C32H28N4O6] |
|
| F | H | 3 | 75 | 117 | 65.42 (65.49) | 4.37 (4.43) | 9.78 (9.85) | 569 [C31H25FN4O6] |
|
| OCH3 | H | 2 | 80 | 110 | 66.16 (66.20) | 4.79 (4.86) | 9.59 (9.65) | 581 [C32H28N4O7] |
|
| Cl | H | 3 | 72 | 128 | 63.59 (63.65) | 4.29 (4.31) | 9.52 (9.58) | 586 [C31H25ClN4O6] |
|
| Br | H | 3 | 78 | 176 | 59.08 (59.15) | 3.94 (4.00) | 8.88 (8.90) | 629 [C31H25BrN4O6] |
|
| NO2 | H | 3 | 70 | 164 | 62.47 (62.52) | 4.19 (4.23) | 11.72 (11.76) | 596 [C31H25N5O8] |
|
| H | Cl | 3 | 78 | 121 | 63.60 (63.65) | 4.26 (4.31) | 9.50 (9.58) | 586 [C31H25ClN4O6] |
Figure 3Mechanistic pathway for the formation of ethyl 4-(naphthalen-2-yl)-2-oxo-6-phenylcyclohex-3-enecarboxylates and (2E)-ethyl2- (2-(2,4-dinitrophrnyl)hydrazono)-4-(naphthalen-2-yl)-6-arylcyclohex-3-enecarboxylates
In-vitro antibacterial activity (MIC) values for (2E)-ethyl-2-(2-(2,4-dinitrophenyl)hydrazono)-4-(naphthalen-2-yl)-6-arylcyclohex-3-enecarboxylates (compounds 17-24)
|
|
| ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
|
| 100 | 100 | 200 | 100 | 50 | 50 | 6.25 |
|
| 200 | 100 | - | 100 | 12.5 | 6.25 | 12.5 |
|
| 6.25 | 6.25 | 25 | 6.25 | 12.5 | 6.25 | 25 |
|
| 200 | - | 200 | 200 | 6.25 | 12.5 | 12.5 |
|
| 12.5 | 25 | 6.25 | 12.5 | 12.5 | 25 | 6.25 |
|
| 25 | 25 | 100 | 6.25 | 100 | 25 | 50 |
|
| 25 | 12.5 | 50 | 6.25 | 6.25 | 25 | 12.5 |
|
| 25 | 12.5 | 25 | 25 | 12.5 | 6.25 | 50 |
| Ciprofloxacin | 25 | 25 | 50 | 25 | 25 | 50 | 25 |
a - No inhibition even at higher concentration i.e., at 200 μg/mL
In-vitro antifungal activity (MIC) values for (2E)-ethyl-2-(2-(2,4-dinitrophenyl) hydrazono)-4-(naphthalen-2-yl)-6-arylcyclohex-3-enecarboxylates (compounds 17-24).
|
|
| ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
|
| 200 | 100 | 100 | 200 | -a |
|
| 25 | 25 | 6.25 | 12.5 | 25 |
|
| 6.25 | 6.25 | 25 | 12.5 | 6.25 |
|
| 25 | 12.5 | 12.5 | 6.25 | 25 |
|
| 12.5 | 6.25 | 25 | -a | 6.25 |
|
| 6.25 | 6.25 | 25 | 12.5 | 25 |
|
| -a | 50 | 6.25 | 100 | 25 |
|
| 6.25 | 6.25 | 12.5 | 100 | 25 |
| Fluconazole | 50 | 50 | 25 | 25 | 25 |
a - No inhibition even at higher concentration i.e., at 200 μg/mL